NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
2.80
Dollar change
-0.30
Percentage change
-9.72
%
Index- P/E- EPS (ttm)-5.71 Insider Own17.77% Shs Outstand3.15M Perf Week-26.45%
Market Cap8.80M Forward P/E- EPS next Y-1.02 Insider Trans0.00% Shs Float2.59M Perf Month-0.89%
Enterprise Value6.34M PEG- EPS next Q-0.68 Inst Own7.93% Short Float8.50% Perf Quarter18.43%
Income-11.67M P/S- EPS this Y71.90% Inst Trans-73.72% Short Ratio3.64 Perf Half Y-8.36%
Sales0.00M P/B- EPS next Y47.69% ROA-185.71% Short Interest0.22M Perf YTD-8.36%
Book/sh-0.39 P/C3.58 EPS next 5Y50.14% ROE-538.87% 52W High4.10 -31.83% Perf Year5.08%
Cash/sh0.78 P/FCF- EPS past 3/5Y51.76% 54.16% ROIC- 52W Low1.72 62.50% Perf 3Y-96.78%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility10.86% 9.14% Perf 5Y-96.57%
Dividend TTM- EV/Sales- EPS Y/Y TTM18.85% Oper. Margin- ATR (14)0.29 Perf 10Y-100.00%
Dividend Ex-Date- Quick Ratio0.73 Sales Y/Y TTM- Profit Margin- RSI (14)44.44 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.73 EPS Q/Q79.84% SMA20-9.83% Beta1.37 Target Price11.00
Payout- Debt/Eq- Sales Q/Q- SMA503.34% Rel Volume2.09 Prev Close3.10
Employees1 LT Debt/Eq- EarningsMay 19 SMA20010.29% Avg Volume60.43K Price2.80
IPOMar 17, 1980 Option/ShortNo / Yes EPS/Sales Surpr.0.00% - Trades Volume126,283 Change-9.72%
Date Action Analyst Rating Change Price Target Change
Dec-02-24Initiated ROTH MKM Buy $11
May-24-21Initiated H.C. Wainwright Buy $25
Apr-13-21Initiated B. Riley Securities Buy $21
Mar-17-21Initiated ROTH Capital Buy $25
Jun-13-25 09:00AM
May-19-25 09:00AM
May-15-25 09:00AM
May-14-25 07:00AM
Mar-04-25 07:00AM
02:00PM Loading…
Feb-25-25 02:00PM
07:00AM
Jan-27-25 07:00AM
Nov-14-24 04:00PM
Sep-26-24 09:15AM
Sep-24-24 09:15AM
Aug-14-24 09:54PM
04:05PM
Jun-27-24 09:15AM
May-21-24 09:15AM
08:40AM Loading…
May-20-24 08:40AM
07:36AM
May-16-24 10:53AM
May-15-24 05:00PM
Mar-26-24 09:53PM
05:00PM
Feb-01-24 11:00AM
Dec-06-23 09:30AM
Dec-04-23 09:30AM
Nov-06-23 09:30AM
Nov-01-23 09:00AM
Aug-07-23 09:00AM
Aug-03-23 01:25PM
May-15-23 05:00PM
May-04-23 09:05AM
07:07AM Loading…
Apr-12-23 07:07AM
Mar-30-23 05:00PM
Feb-24-23 09:00AM
Feb-02-23 09:46AM
Dec-30-22 08:00AM
Dec-14-22 07:30AM
Dec-12-22 07:30AM
Nov-10-22 03:15PM
Nov-03-22 09:00AM
Oct-31-22 05:15PM
Oct-25-22 02:44PM
Oct-06-22 08:18AM
Oct-04-22 04:10PM
Sep-12-22 09:34AM
Sep-08-22 07:30AM
Aug-30-22 06:00PM
Aug-11-22 09:35AM
Jun-10-22 08:00AM
May-19-22 07:45AM
May-16-22 08:01AM
May-12-22 08:00AM
Apr-11-22 07:30AM
Mar-28-22 04:15PM
Mar-21-22 07:30AM
Mar-09-22 04:24PM
Mar-03-22 07:30AM
Feb-24-22 07:30AM
Feb-18-22 07:30AM
Jan-20-22 07:30AM
Jan-06-22 04:30PM
Jan-04-22 05:38PM
Dec-08-21 07:30AM
Nov-30-21 07:30AM
Nov-24-21 04:05PM
Nov-17-21 07:28AM
Nov-10-21 04:10PM
Nov-08-21 07:30AM
Oct-07-21 10:00AM
Sep-20-21 07:00AM
Sep-16-21 12:00PM
Sep-15-21 07:00AM
Sep-13-21 07:00AM
Sep-09-21 07:00AM
Sep-08-21 12:28PM
Aug-23-21 07:00AM
Aug-13-21 07:30AM
Aug-06-21 08:00AM
Aug-03-21 07:00AM
Jul-28-21 08:00AM
Jul-16-21 03:13AM
Jul-07-21 08:00AM
Jun-24-21 08:00AM
Jun-23-21 08:00AM
Jun-21-21 08:00AM
Jun-16-21 08:00AM
Jun-08-21 08:00AM
May-18-21 09:50AM
May-17-21 06:54PM
May-12-21 07:00AM
Apr-26-21 07:00AM
Apr-19-21 07:00AM
Apr-12-21 08:00AM
Apr-08-21 08:00AM
Mar-29-21 07:00AM
Mar-17-21 08:00AM
Mar-10-21 08:00AM
Mar-08-21 08:30AM
Mar-04-21 08:30AM
Mar-02-21 03:00AM
Feb-18-21 08:00AM
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.